These highlights do not include all the information needed to use TRESIBA safely and effectively. See full prescribing information for TRESIBA.
TRESIBA® (insulin degludec injection), for subcutaneous use
Initial U.S. Approval: 2015
INDICATIONS AND USAGE
TRESIBA is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus (1).
Limitations of Use:
Not recommended for treating diabetic ketoacidosis.
DOSAGE AND ADMINISTRATION
-
•
-
Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results and glycemic control goal ( 2.1, 2.2, 2.3, 2.4).
-
•
-
Rotate injection sites to reduce the risk of lipodystrophy ( 2.1).
-
•
-
Do not dilute or mix with any other insulin or solution ( 2.1).
-
•
-
Administer subcutaneously once daily at any time of day ( 2.2).
-
•
-
Do NOT perform dose conversion when using the TRESIBA U-100 or U-200 FlexTouch pens. The TRESIBA U-100 and U-200 FlexTouch pens dose window shows the number of insulin units to be delivered and NO conversion is needed ( 2.2).
DOSAGE FORMS AND STRENGTHS
TRESIBA is available in the following package sizes:
-
•
-
100 units/mL (U-100): 3 mL FlexTouch ® ( 3).
-
•
-
200 units/mL (U-200): 3 mL FlexTouch ® ( 3).
CONTRAINDICATIONS
